ClinicalTrials.gg
TerminatedNCT00412698ETERNALUpdated Dec 10, 2010

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

A Phase 3 interventional study of rimonabant and Placebo in Obesity and Dyslipidemias, sponsored by Sanofi. Terminated at 15 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-12-10.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision has been taken in light of recent demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
645
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.

Enrollment
10th of 21
645 · median 643
Started
2006
with 3 others
Phase 3
18 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
19 of 21
Sanofi

Among the 21 studies testing rimonabant in Obesity, this one is the 10th largest by enrollment, is one of 4 that started in 2006, is one of 18 in phase 3, and was the 11th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing rimonabant in Obesity as a file.
02

Study summary

Primary :

To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with dyslipidemia with or without other associated comorbidities.

Main Secondary :

To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic and lipid parameters.

To assess the safety of 12 months Rimonabant treatment versus placebo in these patients.

In selected sites, a sub study will be conducted to determine the effect of 12 months of Rimonabant on additional lipoprotein and inflammatory parameters.

03

Conditions studied

  • Obesity
  • Dyslipidemias
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 27 kg/m² and \< 40 kg/m²,
  • Waist Circumference > 88 cm in women; > 102 cm in men,
  • HDL cholesterol \< 40 mg/dL (1.03 mmol/L) for men; \< 50 mg/dL (1.29 mmol/L) for women, and/or Triglycerides ≥ 150 mg/dL (1.69 mmol/L),
  • LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of statins and/or Ezetimibe therapy for at least 8 weeks prior to screening

Concomitant medications:

  • Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must be at fixed and stable dose for at least 8 weeks prior to screening visit,
  • Patients, who are willing and in the opinion of the Investigator safely assumed to remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe without adding additional medications or changing current treatment for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed (excluded by pregnancy test),
  • Absence of medically approved methods for female of ,
  • History of very low-calorie diet within 3 months prior to screening visit (lower than 1200 Kcal/day),
  • Weight change > 5 kg within 3 months prior to screening visit,
  • History of surgical procedures for weight loss (e.g., stomach stapling, bypass),
  • History of bulimia or anorexia nervosa as per criteria
  • Presence of any endocrine disease according to the investigator, in particular known abnormal TSH and free T4 blood level (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status),
  • Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood glucose ≥ 126 mg/dl,
  • Triglyceride level > 400 mg/dL (4.52 mmol/L),
  • Systolic blood pressure > 160 mm Hg or diastolic blood pressure >100 mmHg at screening visit,
  • Known severe renal dysfunction ( \< 30 ml/min) or nephrotic syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more protein,
  • Known severe hepatic impairment or and/or ALT > 3 times the at screening,
  • Presence of any condition (medical, including clinically significant abnormal laboratory tests, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study. In particular :

    • Cardiac abnormalities: cardiac failure status III or IV, relevant acute abnormal finding seen on at screening or within 6 months before screening,
    • Any current or any cancer within the past five years (except adequately treated basal cell skin cancer or cervix carcinoma in situ),
    • Significant haematology abnormalities ( \< 100 g/L and/or neutrophils \< 1.5 G/L and/or \< 100 G/L),
    • Acute psychiatric disorders, or mental condition which could interfere with the patient's compliance or safe participation in the study,
    • Patient treated for epilepsy
  • Ongoing major depressive illness,
  • Uncontrolled psychiatric illness,
  • History of alcohol or other substance abuse,
  • /intolerance to the active substance or to any of the such as lactose,

Concomitant medications prior to study entry::

  • Administration of any treatment (drug or device) within 30 days prior to screening,
  • Previous participation in a Rimonabant study or previous administration of Rimonabant,
  • Administration of any of the following within 3 months prior to screening visit:

    • anti obesity drugs (eg, sibutramine, orlistat),
    • other drugs for weight reduction (phentermine, amphetamines),
    • herbal preparations for weight reduction,
    • nicotinic acid, fibrates or bile acid sequestrants,
    • Prolonged use (more than one week) of systemic , neuroleptics,
    • Omega-3 fatty acid approved medication
  • Ongoing antidepressive treatment (including bupropion)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
645 participants (actual)

Study arms

  • Experimental
    1

    Drug: rimonabant

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning. White film-coated tablets, for oral administration containing 20 mg of active rimonabant

  • DrugPlacebo

    Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.

06

What researchers measure

Primary outcomes

  1. Change in HDL-C and triglyceride levels

    Time frame: From baseline to end of treatment

Secondary outcomes

  1. Waist circumference and body weight

    Time frame: At each visit

  2. Glycemic parameters : FPG, fasting insulinemia, HbA1c,

    Time frame: Prior to baseline, month 3, month 6 and month 12.

  3. Lipid parameters : Total Cholesterol, HDL-C, LDL-C, triglyceride levels

    Time frame: Prior to baseline, month 3, month 6 and month 12.

  4. Inflammatory parameter : Hs-CRP

    Time frame: Prior to baseline, month 3, month 6 and month 12.

  5. Quality of life : IWQOL questionnaire completed

    Time frame: At baseline, month 3, month 6, month 9 and month 12.

  6. Incidence of adverse events in each group, including neuro-psychiatric adverse events

    Time frame: Prior to baseline, month 3, month 6 and month 12.

  7. Standard laboratory assessments

    Time frame: Prior to baseline and month 12

  8. In selected sites, a sub study will be conducted in which additional Lipid parameters will be measured: HDL subfractions, Apo A1, Apo A2, Apo B and Apo C3, Lp A1, LpA1/A2, Lp(a), Oxidized-LDL and LDL size

    Time frame: Prior to baseline and at month 12

  9. In selected sites, a sub study will be conducted in which additional Inflammatory parameters will be measured: Adiponectin-High Molecular Weight, Intracellular adhesion molecule 1(ICAM-I) and TNFalpha.

    Time frame: Prior to baseline and at month 12

07

Study locations

15 sites
  • Sanofi-Aventis Administrative Office
    Prague, Czech Republic
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Dublin, Ireland
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Lysaker, Norway
  • Sanofi-Aventis Administrative Office
    Porto-Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Bratislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Stockholm, Sweden
  • Sanofi-Aventis Administrative Office
    Meyrin, Switzerland
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Guildford, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2006
First posted
Dec 18, 2006
Start
Dec 2006
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Last update
Dec 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00412698
Lead sponsor
Sanofi
First posted
Dec 18, 2006
Start date
Dec 2006
Primary completion
Jan 2009
Completion
Jan 2009
Last update
Dec 10, 2010

Study contacts

Valérie Pilorget, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion